Rigel Pharmaceuticals
Tavalisse (fostamatinib), a SYK inhibitor small-molecule therapeutic
- Sector
- Biotech
- Total capital
- $750K
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $750K
- 1 award · Health and Human S
- Rank in Biotech#206 of 4373
- Granted patents
- 22
- 18 pending · first 2023
- Rank in peer group#5 of 1449
Capital timeline
Latest events
- Federal contractHealth and Human S · Rigel Pharmaceuticals: The Overall Objective Of This Contract Is To Evaluate The Impact Of Fostamatinib Treatment During Hospitalization Resulting From Ards On Long-term Outcomes Including Clinical, Biomarker, Imaging, Qol, Functional And Lung Functi$750K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#5 · top 1%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 22 granted of 40- New patentMethod Of Preparing PralsetinibUSPTOUS 12,747,226
- PendingPyrazole Compounds, Formulations Thereof, And A Method For Using The Compounds And/or FormulationsUSPTOApplication 19319595
- GrantedPralsetinib Pharmaceutical CompositionsUSPTOUS 12,692,251
Show all 40 patent records
- Method Of Preparing PralsetinibSep 29, 2026 · US 12,747,226Granted
- Pyrazole Compounds, Formulations Thereof, And A Method For Using The Compounds And/or FormulationsSep 10, 2026 · Application 19319595Pending
- Pralsetinib Pharmaceutical CompositionsJul 28, 2026 · US 12,692,251Granted
- Inhibitors Of RetJun 16, 2026 · US 12,655,128Granted
- Pharmaceutical CompositionsJun 11, 2026 · Application 19410904Pending
- Solid Forms Of 1-(4-(4-((3-(3,6-DIFLUOROPYRIDIN-2-YL)-1-((1R,4R)-4-ETHOXYCYCLOHEXYL)-1H-PYRAZOL-4-YL)CARBAMOYL)THIAZOL-2-YL)-1H-PYRAZOL-1-YL)ETHYL Phosphate And Salts Thereof, And Their Pharmaceutical Compositions And UsesJun 11, 2026 · Application 19411088Pending
- Methods Of TreatmentJun 11, 2026 · Application 19198985Pending
- Method For Treating A Disease Or Condition Using A Pyrazole Compound Or Formulation ThereofMay 7, 2026 · Application 19238300Pending
- Solid Forms Of PralsetinibApr 23, 2026 · Application 19327837Pending
- Ret Inhibitor For Use In Treating Cancer Having A Ret AlterationFeb 3, 2026 · US 12,539,303Granted
- Tricyclic Irak InhibitorsNov 4, 2025 · US 12,459,941Granted
- PYRIMID-2-YL-PYRAZOLE Compounds As Irak InhibitorsOct 30, 2025 · Application 19262001Pending
- Pyrazole Compounds And Method For Making And Using The CompoundsOct 23, 2025 · Application 18963039Pending
- Solid Forms Of PralsetinibOct 21, 2025 · US 12,448,366Granted
- Pyrazole Compounds, Formulations Thereof, And A Method For Using The Compounds And/or FormulationsOct 14, 2025 · US 12,441,723Granted
- Treatment Of Cns Tumors With Olutasidenib And TemozolomideSep 4, 2025 · Application 19068996Pending
- PYRIMID-2-YL-PYRAZOLE Compounds As Irak InhibitorsAug 12, 2025 · US 12,384,775Granted
- Method For Treating A Disease Or Condition Using A Pyrazole Compound Or Formulation ThereofJul 15, 2025 · US 12,357,623Granted
- Heterocyclic RIP1 Kinase InhibitorsJun 17, 2025 · US 12,331,036Granted
- RIP1K InhibitorsMay 13, 2025 · US 12,297,202Granted
- Method For Treatment Of COVID-19-ASSOCIATED ConditionsApr 1, 2025 · US 12,263,180Granted
- Heterocyclic RIP1 Inhibitory CompoundsMar 20, 2025 · Application 18899350Pending
- TGF-ß INHIBITORSFeb 18, 2025 · US 12,227,508Granted
- RIP1 Inhibitory Compounds And Methods For Making And Using The SameJan 30, 2025 · Application 18890094Pending
- Crystalline Forms Of A RIPK1 InhibitorJan 16, 2025 · Application 18711541Pending
- Formulations And Dosing Regimens For RIP1 Kinase Inhibitors For Treating Autoimmune And Inflammatory DiseasesJan 2, 2025 · Application 18745814Pending
- Heterocyclic RIP1 Kinase InhibitorsDec 3, 2024 · US 12,156,880Granted
- Irak Inhibitor for Treating Cytokine Release-Related Conditions Associated With Infection by a Respiratory VirusNov 21, 2024 · Application 18690705Pending
- RIP1 Inhibitory Compounds And Methods For Making And Using The SameNov 7, 2024 · Application 18621266Pending
- RIP1 Inhibitory Compounds And Methods For Making And Using The SameOct 15, 2024 · US 12,116,354Granted
- Benzazole Compounds And Methods For Making And Using The CompoundsJul 23, 2024 · US 12,043,620Granted
- RIP1K InhibitorsJul 23, 2024 · US 12,043,629Granted
- RIP1 Inhibitory Compounds And Methods For Making And Using The SameJul 4, 2024 · Application 18432727Pending
- Irak Inhibitors And Method For Making And UsingMay 28, 2024 · US 11,993,594Granted
- Ret Inhibitor For Use In Treating Cancer Having A Ret AlterationApr 23, 2024 · US 11,963,958Granted
- Amide Compounds And Method For Making And UsingMar 26, 2024 · US 11,939,317Granted
- RIP1 Inhibitory Compounds And Methods For Making And Using The SameMar 5, 2024 · US 11,919,890Granted
- Method Of Preparing PralsetinibFeb 22, 2024 · Application 18255402Pending
- Bicyclic Inhibitors Of IrakDec 7, 2023 · Application 18204304Pending
- Compositions And Methods For Inhibition Of The Jak PathwayNov 28, 2023 · US 11,827,628Granted
Related companies, and why
- JUMPCODE GENOMICSSimilar federal contract value in Biotech · $765K in contracts
- GenomaticaSimilar federal contract value in Biotech · $761K in contracts
- ATUX ISKAY GROUP LLCSimilar federal contract value in Biotech · $755K in contracts
- GRYPHON BIO INCSimilar federal contract value in Biotech · $749K in contracts
- RenBio, Inc.Similar federal contract value in Biotech · $749K in contracts
- GEN1E LIFESCIENCES INC.Similar federal contract value in Biotech · $749K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .